List of contributor Preface 1. INTRODUCTION TO RADIONUCLIDE THERAPY; J. Carlsson et al. 2. THERAPEUTICALLY USED ANTIGENS IN RADIOIMMUNOTHERAPY; T. Stigbrand et al. 3. EGFR-FAMILY EXPRESSION AND IMPLICATIONS FOR TARGETED RADIONUCLIDE THERAPY; J. Carlsson 4. TARGETING TUMORS WITH RADIOLABELED ANTIBODIES; T. Stigbrand et al. 5. ANTOBODY FRAGMENTS PRODUCED BY RECOMBINANT AND PROTEOLYTOC METHODS; G. Adams 6. NOVEL ALTERNATIVE SCAFFOLDS AND THEIR POTENTIAL USE FOR TUMOR TARGETED RADIONUCLIDE THERAPY; F. Nilsson 7. PEPTIDES FOR RADIONUCLIDE THERAPY; M. de Jong et al. 8. CHOICE OF RADIONUCLIDES AND RADIOLABELLING TECHNIQUES; V. Tolmachev 9. HIGH-LET-EMITTING RADIONUCLIDES FOR CANCER THERAPY; G. Sgouros 10. TARGETED HIGH-LET THERAPY OF BONE METASTASES; Ø. S. Bruland et al. 11. THE AUGER EFFECT IN MOLECULAR TARGETING THERAPY; H. Lundqvist et al. 12. RADIATION INDUCED CELL DEATHS; D. Eriksson et al. 13. RADIATION INDUCED DNA-DAMAGE/REPAIR AND ASSOCIATED SIGNALING PATHWAYS; B. Stenerlöw et al. 14. RADIATION INDUCED DNA DAMAGE CHECKPOINTS; D. Eriksson et al. 15. CANCER STEM CELLS AND RADIATION; D. Eriksson et al. 16. EFFECTS OF LOW DOSE-RATE RADIATION ON CELLULAR SURVIVAL; J. Carlsson 17. BYSTANDER EFFECTS AND RADIONUCLIDE THERAPY; K. M. Prise 18. ENHANCING THE EFFICIENCY OF TARGETED RADIONUCLIDE TREATMENT; G. Adams 19. LOW DOSE HYPERRADIOSENSITIVITY: A HISTORICAL PERSPECTIVE; B. Marples et al. 20. CLINICAL RADIONUCLIDE THERAPY: A. Scott and S. Lee 21. DEVELOPMENT TRENDS IN TARGETED THERAPY-BIOLOGICAL ASPECTS; T. Stigbrand et al.
The last three decades have provided opportunities to explore the potential of treating malignant diseases with antibodies or other targeting molecules labelled with nuclides. While considerable advances have been reported, there is still a signi- cant amount of work left to accomplish before our ambitions can be achieved. It now seems timely to review the accomplishments achieved to date and to clarify the challenges that remain. The choice of radionuclide, the conjugation p- cedure employed, and the selection of suitable targets were early issues that were faced by our field that still persist, however we can now tackle these obstacles with significantly better insight. The expanding array of new targeting molecules (recombinant antibodies, peptides and agents based upon alternate scaffolds) may increase the therapeutic efficacy or even modify the radiation sensitivity of the targeted tumor cell. The title of this book "Targeted Radionuclide Tumour Therapy - Biological Aspects" was selected to reinforce the concept that a major focus of this volume was devoted to understanding the biological effects of targeting and radiation. These important issues have not previously been the primary focus in this context. Furthermore, our rapidly expanding knowledge of different types of cell death and the increasingly likely existence of cancer stem cells suggests to us that even more efficient approaches in targeting might be possible in the future.
Focus on biological effects of targeted radionuclide therapy
Comprehensive presentation of different mechanisms of tumor cell death
Up-to-date presentation of new targeting agents
Summaries of present state of clinical applications of targeted therapy
Introduction of the new concept; Autosensitization during radionuclide therapy